Pacific Edge Ltd news
Pacific Edge is pleased to announce today that it has reached its first commercial agreement of scale in Australia with Northern Health, a major provider of healthcare and hospital services to Melbourne’s rapidly growing outer northern suburbs.
Northern Health provides healthcare services to the rapidly growing suburbs in Melbourne’s outer north through four campuses across the region, with over 5,700 professional staff. Northern Health’s urology needs make it s
Pacific Edge is pleased to report continuing growth for the six months ended 30 September 2021 (1H22), with key performance metrics significantly ahead of the same time last year, driven by reimbursement milestones, increasing insurance coverage and adoption by urologists and healthcare organisations.
Summary of performance for the period (% changes compared to prior comparative period (pcp)):
Pacific Edge advises that its half year results for the six months ending 30 September 2021 will be released on Thursday 25 November 2021, prior to 10am.
This will be followed by an Investor and Analyst conference call at 10.30am (NZST). This investor briefing will be available via a webcast (presentation slides and audio only) or ‘audio only’ service. Please follow the instructions outlined below to access the event.
To join the investor
Pacific Edge today announces the appointment of Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer.
Dr Meintjes, a New Zealand citizen currently resident in Boston, brings to Pacific Edge extensive global diagnostics, biotechnology, and commercial leadership expertise. He also has a track record for commercialising new and disruptive biotechnologies and driving rapid business growth across multiple territories inclu
Pacific Edge has once again been named in the Deloitte Fast 50 Awards, as it continues to execute on its commercial strategy and drive revenue growth.
Pacific Edge was named 48th in the Fast 50 Index and the fastest growing export business for Dunedin and Lower South Island.
The company, which has recently completed a highly successful and well supported capital raise, is now well positioned to accelerate its growth, with recent commercial milestones, clinical validation and t